These firms are in the forefront of the cancer wars, and their stocks should deliver healthy gains.
Medical science hasn’t yet won the war on cancer, but it is scoring important victories in battles against many forms of the dreaded disease. Advances in new treatments have made cancer a hot investing theme over the past 18 months, helping to power fresh interest in biotechnology stocks.
Companies such as Medivation have fueled the renewed lure of striking it rich from novel cancer treatments. With Xtandi—its breakthrough treatment for prostate cancer—riding high, plus promising new drugs for breast cancer and blood cancers in development, the company was the object of a bidding war in 2016. It culminated last September with drug giant Pfizer (symbol PFE) paying $14 billion for Medivation, or $81.50 per share—38 times the stock’s level at its 2010 low.
In February, Japan’s Takeda Pharmaceuticals (TKPYY) paid $5.2 billion for Ariad Pharmaceuticals (ARIA), which is developing drugs that target certain solid tumors. The buyout price was 75% above Ariad’s market value before the deal was announced.
Plenty of volatility. Biotech shares had led the bull market overall, with a New York Stock Exchange–sponsored index of 30 biotech issues soaring 723% from early 2009 to mid 2015. But the stocks then dived 42% by February 2016, in part because of a political backlash against high drug prices.
That backlash remains a long-term threat to the industry’s profit potential, and it continues to weigh on the stocks. Despite a rebound since early 2016, the NYSE biotech index is still down 20% from its 2015 peak. But that could also mean opportunity.
Denne historien er fra June 2017-utgaven av Kiplinger's Personal Finance.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra June 2017-utgaven av Kiplinger's Personal Finance.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
My Top 30 Index: An Update
A year ago, I put together what I called \"my own reinvention\" of the Dow Jones industrial average, the popular 142-year-old large-cap index.
Balance Your Risk and Reward
These new ETFs let you cut stock market losses. But you'll sacrifice some gains.
IS A HYBRID CAR RIGHT FOR YOU?
Hybrids offer a fuel-saving option for drivers who have reservations about all-electric vehicles. But there are trade-offs.
HOW TO REACH YOUR INVESTING GOALS
Patience helped these four investors make their portfolios work for them.
WHERE TO INVEST NOW
Expect a lot of midyear churn, with a rally toward the end of 2024.
TIPS FOR FINANCING A HOME PROJECT
I recently had a call with a client who was looking to fund the construction of a swimming pool at his house.
MORE WOMEN THAN EVER ARE STARTING BUSINESSES
Retail and travel businesses, along with health, beauty and fitness, are popular with women entrepreneurs.
Finding Home Health Care
It’s important to hire a caregiver you trust.
UNDERSTANDING BOND FUND YIELDS
What's a 30-day SEC yield? A trailing 12-month yield? A yield to maturity? We explain what each measure says about an income fund.
ANSWERS TO YOUR QUESTIONS ON STUDENT LOANS
If you have federal student loans, you may benefit from new government policies. Here's what you need to know.